Display options
Share it on

Clin Ophthalmol. 2016 Dec 20;11:39-46. doi: 10.2147/OPTH.S115685. eCollection 2017.

Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of life.

Clinical ophthalmology (Auckland, N.Z.)

Myrte B Breukink, Alexander Jm Dingemans, Anneke I den Hollander, Jan Ee Keunen, Robert E MacLaren, Sascha Fauser, Giuseppe Querques, Carel B Hoyng, Susan M Downes, Camiel Jf Boon

Affiliations

  1. Department of Ophthalmology.
  2. Department of Ophthalmology; Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.
  3. Oxford Eye Hospital, Oxford University Hospitals NHS Trust; Nuffield Laboratory of Ophthalmology and NIHR Biomedical Research Centre, Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  4. Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany.
  5. Department of Ophthalmology, University Paris Est Creteil, Centre Hospitalier Intercommunal de Creteil, Creteil, France.
  6. Department of Ophthalmology; Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.

PMID: 28053499 PMCID: PMC5189979 DOI: 10.2147/OPTH.S115685

Abstract

PURPOSE: To describe the clinical findings and long-term outcome of patients with chronic central serous chorioretinopathy (cCSC).

MATERIALS AND METHODS: This was a retrospective case series in 52 eyes of 36 patients with a follow-up period of at least 1 year. Extensive ophthalmic examination and a validated questionnaire concerning vision-related quality of life (National Eye Institute Visual Function Questionnaire [NEI-VFQ]-39) were analyzed.

RESULTS: Mean visual acuity showed a significant decline over time of 0.16 logarithm of minimum angle of resolution ([logMAR] range: -0.22 to 1.3;

CONCLUSION: This study indicates that cCSC is a progressive disease in many patients, causing a progressive decline in visual acuity, accompanied by lower reported vision-related quality of life. In deciding whether or not to treat, the progressive nature of cCSC should be taken into account in this relatively young and often still professionally active patient group.

Keywords: NEI-VFQ-39; PDT; chronic central serous chorioretinopathy; micropulse laser; vision-related quality of life

Conflict of interest statement

Dr Camiel JF Boon was supported by a Niels Stensen Fellowship. The authors report no conflicts of interest in this work.

References

  1. Ophthalmology. 2015 Mar;122(3):562-70 - PubMed
  2. Arch Ophthalmol. 2001 Jul;119(7):1050-8 - PubMed
  3. Health Qual Life Outcomes. 2013 Jan 24;11:10 - PubMed
  4. Arch Ophthalmol. 1994 Aug;112(8):1057-62 - PubMed
  5. Ophthalmology. 2014 May;121(5):1067-72 - PubMed
  6. Retina. 2013 Sep;33(8):1659-72 - PubMed
  7. Exp Eye Res. 1973 Jan 1;15(1):15-29 - PubMed
  8. Am J Ophthalmol. 2002 Jun;133(6):787-93 - PubMed
  9. Eye (Lond). 2001 Jun;15(Pt 3):384-9 - PubMed
  10. Br J Ophthalmol. 2013 Sep;97(9):1181-6 - PubMed
  11. Surv Ophthalmol. 2013 Mar-Apr;58(2):103-26 - PubMed
  12. Retina. 2000;20(6):633-7 - PubMed
  13. Surv Ophthalmol. 2002 Sep-Oct;47(5):431-48 - PubMed
  14. Eye (Lond). 2011 Dec;25(12):1635-40 - PubMed
  15. Clin Exp Ophthalmol. 2013 Mar;41(2):201-14 - PubMed
  16. Retina. 2010 May;30(5):801-9 - PubMed
  17. Am J Ophthalmol. 1996 Jan;121(1):26-34 - PubMed
  18. Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3629-35 - PubMed
  19. Psychol Bull. 2014 Nov;140(6):1582-607 - PubMed
  20. Prog Retin Eye Res. 2010 Mar;29(2):144-68 - PubMed
  21. Am J Ophthalmol. 2014 Dec;158(6):1155-1163.e1 - PubMed
  22. Retina. 2008 Jul-Aug;28(7):1008-12 - PubMed
  23. Invest Ophthalmol Vis Sci. 1994 May;35(6):2857-64 - PubMed
  24. Arch Ophthalmol. 1995 May;113(5):655-60 - PubMed

Publication Types